A disciplined portfolio, built for durability.

pipeline

Our pipeline expands access through high-impact and specialized biosimilars, ensuring long-term supply.

Biosimilars pipeline

Each program is advanced with lifecycle accountability, from early development through commercial supply.

Program
Reference drug
Therapeutic area
Status
Partner
Ranibizumab
Reference Drug
Lucentis® (Novartis)
Therapeutic area
Ophthalmology
Status
Commercialized
partner
Sandoz, MS Pharma
Read more
Natalizumab
Reference Drug
Tysabri® (Biogen)
Therapeutic area
Neuroimmunology
Status
Commercialized
partner
Sandoz (Global)
Read more
Vedolizumab
Reference Drug
Entyvio® (Takeda)
Therapeutic area
Gastroenterology / Immunology
Status
partner
Fresenius Kabi, MS Pharma
Read more
Ocrelizumab
Reference Drug
Ocrevus® (Roche/Genentech)
Therapeutic area
Neuroimmunology
Status
partner
TEVA, MS Pharma, Libbs
Read more
Guselkumab
Reference Drug
Tremfya® (Johnson & Johnson/Janssen)
Therapeutic area
Immunology
Status
partner
MS Pharma
Read more
Undisclosed-1
Reference Drug
-
Therapeutic area
Hematology
Status
partner
-
Undisclosed-2
Reference Drug
-
Therapeutic area
Oncology
Status
partner
-
Undisclosed-3
Reference Drug
-
Therapeutic area
Rare disease
Status
partner
-
Undisclosed-4
Reference Drug
-
Therapeutic area
Immunology
Status
partner
-
Undisclosed-5
Reference Drug
-
Therapeutic area
Ophthalmology
Status
partner
-
trusted worldwide
More
development

Developing biosimilars requires advanced analytics, deep process knowledge, and rigorous comparability across the product lifecycle.

process

How we are mastering biosimilar complexity

Explore our development approach.

1

A true match

Biosimilars are not exact replicas of the reference product; they are designed to show equivalent safety, efficacy, and quality through thorough scientific comparison.

2

Regulatory scrutiny

Approval requires extensive analytical, clinical, and manufacturing evidence reviewed by EMA, FDA, and other major ealth authorities.

3

Scientific complexity

Unlike small-molecule generics, biologics are produced in living cells, making manufacturing consistency and comparability a scientific challenge at every stage.

Let's build together.

If you want to explore what a partnership with us
could look like, we're ready to talk.

Headquarters

Polpharma Biologics International AG,
Erlenring 2, 6343 Rotkreuz, Switzerland office@polpharmabiologics.ch

About us
What we do
Pipeline
Insights
Careers
Partnerships
Contact
Cookie center
Terms of use
Imprint
Privacy policy
Cookies policy
Code of conduct
Third-party code of conduct
© 2026 Polpharma Biologics. All rights reserved.
Made by Widelab
Precision starts with a conversation.

Tell us about your program, your molecule, or your question. We'll take it from there.

Select subject
subject
Send message
processing of personal data

The controller of your data is Polpharma Biologics International AG. We process your personal data to answer your questions and, if you consent, also for marketing purposes. You have the right to object to the processing, access your data, request its rectification, deletion, transfer or restriction of processing, as well as the right to withdraw consent. Detailed information on the processing of personal data can be found here Privacy policy.

Your message is with the right team.
processing of personal data

The controller of your data is Polpharma Biologics International AG. We process your personal data to answer your questions and, if you consent, also for marketing purposes. You have the right to object to the processing, access your data, request its rectification, deletion, transfer or restriction of processing, as well as the right to withdraw consent. Detailed information on the processing of personal data can be found here Privacy policy.

Oops! Something went wrong while submitting the form.